Skip to content

STERIS STE Life Sciences: — Segment operating income

Other segment segments

Segment operating income
$343.1M+7.2%
Healthcare
$259.5M
Applied Sterilization Technologies
$129.2M+11.6%
Corporate
-$106M-5.2%

Similar metrics at other companies

Revvity logo
RVTYLife Sciences — Segment operating income
$103.98M-1.6%
Ashland logo
ASHLife Sciences — Operating Income
$35M+25.0%
VAT
VATELife Sciences — Income from operations
-$2.2M+26.7%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Operating Income (Loss)
$954M+14.4%
Danaher logo
DHRLife Sciences — Operating Income (Loss)
$225M+11.9%
RCM Technologies logo
RCMTLife Sciences Data Solutions — Operating Income
$2.05M-3.7%

Other financials

Income statement

See full
Revenue$1.6B+7.3%
Gross profit$697.2M+8.8%
Operating income$316.8M+46.6%
Net income$220.2M+51.2%
EPS (diluted)$2.24+52.4%

Balance sheet

See full
Cash & equivalents$439.6M+156%
Total debt$2.1B-10.3%
Total equity$7.2B+8.8%
Total assets$10.7B+5.8%

Cash flow

See full
Operating cash flow$335.4M+28.6%
CapEx$90.2M+27.2%
Free cash flow$245.2M+29.1%

Valuation

See full
Market cap$20.52B-9.4%
Enterprise value$22.17B-8.8%
P/E26.2×-8.8×
P/S3.5×-0.6×

Profitability

See full
Gross margin44.2%+0.2pp
Operating margin18.6%+2.7pp
Net margin13.2%+1.9pp
FCF margin16.4%+2.1pp

Returns & leverage

See full
Return on equity11.3%+1.8pp
Debt / equity0.3×-0.1×
Current ratio2.1×+0.1×

Where this comes from

Reported directly by STERIS in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: STERIS’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about STERIS's life sciences: — segment operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is STERIS's life sciences: — segment operating income?
STERIS (STE) reported life sciences: — segment operating income of $61.8M in Q4 2025.
What does life sciences: — segment operating income mean?
This metric measures the profitability of the Life Sciences segment after accounting for direct costs and allocated operating expenses. It serves as a primary indicator of the segment's operational health and its contribution to the overall corporate bottom line.